Differences in Anaphylaxis Reporting Among Cephalosporins: Analysis of the FDA Adverse Event Reporting System Database

被引：0
|
作者：
Shah, Divya [1 ]
Stone, Cosby [2 ]
Rukasin, Christine [3 ]
机构：
[1] Univ Arizona, Coll Med, Phoenix, AZ USA
[2] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[3] Phoenix Childrens Hosp, Phoenix, AZ USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2024年 / 153卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
233
引用
收藏
页码：AB77 / AB77
页数：1
相关论文
共 50 条
  • [1] Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
    He, Chang-Zhu
    Qiu, Qin
    Lu, Song-Jie
    Xue, Fu-Li
    Liu, Jun-Qiao
    He, Yu
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [2] A Decade of Nintedanib: An Analysis of the FDA Adverse Event Reporting System Database
    Niranjan, S.
    Rao, A.
    Virk, S. T.
    Sarangdhar, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [3] Adverse event signal analysis of remimazolam using the FDA adverse event reporting system database
    Liu, Hongtao
    Li, Zhaoyu
    Yan, Su
    Ming, Shaopeng
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2025, 69 (03)
  • [4] A Disproportionality Analysis of Treprostinil Based on FDA Adverse Event Reporting System Database
    Li, Lingling
    Song, Weiqiang
    Jiao, Wanli
    ANNALS OF PHARMACOTHERAPY, 2024,
  • [5] Novel adverse events of blonanserin: a disproportionality analysis in the FDA Adverse Event Reporting System database
    Subeesh, Viswam
    Singh, Hemendra
    Maheswari, Eswaran
    Beulah, Thomas
    MINERVA PSICHIATRICA, 2018, 59 (02): : 105 - 110
  • [6] Pharmacovigilance of esketamine nasal spray: an analysis of the FDA adverse event reporting system database
    Liu, Ruixue
    Liu, Chunxiao
    Feng, Dianwei
    Guo, Tongxin
    Wang, Ying
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [7] Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database
    Rashid Kazerooni
    Edward P. Armstrong
    Clinical Drug Investigation, 2018, 38 : 867 - 872
  • [8] Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database
    Kazerooni, Rashid
    Armstrong, Edward P.
    CLINICAL DRUG INVESTIGATION, 2018, 38 (09) : 867 - 872
  • [9] Analysis of ADR reports of cetuximab based on the FDA adverse event reporting system database
    Zhao, Shuai
    Wang, Yan
    Deng, Xiaoli
    Chen, Xi
    Lu, Zhaoyi
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [10] Botulinum toxin type A overdoses: analysis of the FDA adverse event reporting system database
    Kazerooni, Rashid
    NEUROLOGY, 2019, 92 (15)
12345